Shareholder Votes

Alphabet Inc. shareholders approved Amendment and restatement of the 2021 Stock Plan to increase the share reserve by 200,000,000 shares of Class C capital stock.

“The amendment and restatement of the 2021 Stock Plan to increase the share reserve by 200,000,000 shares of Class C capital stock was approved.”

Alphabet Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as Alphabet’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.

“The ratification of the appointment of Ernst & Young LLP as Alphabet’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved.”

Alphabet Inc. shareholders approved Election of Directors.

“The individuals listed below were elected at the 2026 Annual Meeting to serve as directors of Alphabet until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified:”

Limbach Holdings, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm (Crowe LLP) at the 2026-06-09 meeting.

“For Against Abstain 10,244,410 159,766 28,071”

Limbach Holdings, Inc. shareholders approved Approval of the frequency of an Advisory Vote on the compensation of our Named Executive Officers via a Non-Binding, Advisory Vote at the 2026-06-09 meeting.

“1 Year 2 Years 3 Years Abstain Broker Non-Votes 8,833,621 137,411 250,819 201,209 1,009,187”

Limbach Holdings, Inc. shareholders approved Approval of the Compensation of Our Named Executive Officers via a Non-Binding, Advisory Vote at the 2026-06-09 meeting.

“For Against Abstain Broker Non-Votes 9,024,193 393,847 5,020 1,009,187”

Limbach Holdings, Inc. shareholders approved Election of Joshua S. Horowitz, Linda G. Alvarado and Terence P. Dugan as Class A directors at the 2026-06-09 meeting.

“Joshua S. Horowitz 8,827,689 595,371 1,009,187 Linda G. Alvarado 6,127,695 3,295,365 1,009,187 Terence P. Dugan 9,337,538 85,522 1,009,187”

Organon & Co. shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“4. To ratify the appointment by the Company's Audit Committee of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm”

Organon & Co. shareholders approved To approve an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan at the 2026-06-09 meeting.

“3. To approve an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan”

Organon & Co. shareholders approved To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2026-06-09 meeting.

“2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”

Organon & Co. shareholders approved Election of ten directors nominated by the Board at the 2026-06-09 meeting.

“On June 9, 2026, the Company held its 2026 Annual Meeting, at which the Company's stockholders considered four proposals”

Zomedica Corp. shareholders approved Amendment to the By-Laws of the Company to address the quorum requirements for an adjourned meeting of Shareholders at the 2026-06-10 meeting.

“Proposal 4 ; Amendment of the Company’s By-Laws The votes cast to approve an amendment to the By-Laws of the Company to address the quorum requirements for an adjourned meeting of Shareholders as described in the our management information circular and proxy statement for the Annual Meeting were as follows: . For: 123,410,315 Against: 105,771,772 Broker Non-Vote 200,401,613”

Zomedica Corp. shareholders rejected Advisory vote to approve the compensation of our named executive officers as described in our management information circular and proxy statement for the Annual Meeting at the 2026-06-10 meeting.

“Proposal 3: Advisory Vote on the Company’s Executive Compensation The votes cast on the advisory vote to approve the compensation of our named executive officers disclosed in our management information circular and proxy statement for the Annual Meeting were as follows: For: 99,891,977 Against: 129,290,109 Broker Non-Vote 200,401,613”

Zomedica Corp. shareholders approved Ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2026 at the 2026-06-10 meeting.

“Proposal 2: Ratification of Independent Auditors For: 403,285,558 Withheld: 26,298,141”

Zomedica Corp. shareholders approved Election of eight directors, each for a one-year term at the 2026-06-10 meeting.

“Proposal 1: Election of Eight Directors For Withheld Broker Non-Vote Jeffrey Rowe 148,970,700 80,211,388 200,401,611 Robert Cohen 141,153,095 88,028,993 200,401,611 Chris Macleod 141,041,101 88,140,987 200,401,611 Pam Nichols 146,791,443 82,390,645 200,401,611 Johnny D. Powers 151,457,102 77,724,986 200,401,611 Sean Whelan 141,437,085 87,745,003 200,401,611 Rodney Williams 141,615,934 87,566,154 200,401,611 Larry Heaton 148,997,578 80,184,510 200,401,611”

CHIMERA INVESTMENT CORP shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the Company for the current fiscal year at the 2026-06-10 meeting.

“Proposal 3 . Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the Company for the current fiscal year. Votes For Votes Against Votes Abstained Broker Non-Votes 62,010,426 750,117 524,922 0 Based on the foregoing votes, the appointment of Ernst & Young LLP as independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.”

CHIMERA INVESTMENT CORP shareholders approved A vote on a non-binding advisory resolution on the Company's executive compensation at the 2026-06-10 meeting.

“Proposal 2 . A vote on a non-binding advisory resolution on the Company’s executive compensation. Votes For Votes Against Votes Abstained Broker Non-Votes 42,287,598 1,901,663 434,042 18,662,162 Based on the foregoing votes, the non-binding advisory resolution on the Company’s executive compensation was approved.”

CHIMERA INVESTMENT CORP shareholders approved Election of three Class I Directors, Kevin G. Chavers, Gerard Creagh and Susan Mills, each to serve until the annual meeting of stockholders in 2029 at the 2026-06-10 meeting.

“Proposal 1 . The election of three Class I Directors, Kevin G. Chavers, Gerard Creagh and Susan Mills, each to serve until the annual meeting of stockholders in 2029. Nominee Votes For Votes Against Votes Abstain Broker Non-Votes (I) Kevin G. Chavers 43,340,068 855,564 427,671 18,662,162 (I) Gerard Creagh 41,637,307 2,558,062 427,934 18,662,162 (I) Susan Mills 43,176,523 1,006,466 440,314 18,662,162 Based on the foregoing votes, Kevin G. Chavers, Gerard Creagh and Susan Mills were elected as Class I Directors each to serve on the Board until the 2029 annual meeting of stockholders and until their successors are duly elected and qualify.”

Shake Shack Inc. shareholders approved Advisory vote on the compensation of named executive officers at the 2026-06-10 meeting.

“Shake Shack’s stockholders approved the advisory resolution approving the compensation of Shake Shack’s Named Executive Officers.”

Shake Shack Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as Shake Shack’s independent registered public accounting firm for the fiscal year ending December 30, 2026 at the 2026-06-10 meeting.

“Shake Shack’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 30, 2026.”

Shake Shack Inc. shareholders approved Election of two Class II directors at the 2026-06-10 meeting.

“Shake Shack’s stockholders elected two nominees, Robert Lynch and Tristan Walker, as Class II directors to hold office until the annual meeting of stockholders to be held during Shake Shack’s 2029 fiscal year and until their respective successor is duly elected and qualified.”

UNIVERSAL HEALTH REALTY INCOME TRUST shareholders approved Ratification of the selection of KPMG, LLP, as the Trust's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

“Proposal No. 3: Ratification of the selection of KPMG, LLP, as the Trust's independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes cast in favor 11,525,347 Votes cast against 114,360 Votes abstained 22,834 Non-votes 0”

UNIVERSAL HEALTH REALTY INCOME TRUST shareholders approved Nonbinding advisory vote on named executive officer compensation at the 2026-06-10 meeting.

“Proposal No. 2: The nonbinding advisory vote on named executive officer compensation: Votes cast in favor 8,955,099 Votes cast against 418,954 Votes abstained 55,422 Non-votes 2,233,065”

UNIVERSAL HEALTH REALTY INCOME TRUST shareholders approved Election of two Class I members of the Board of Trustees for a three-year term scheduled to expire at the Trust's 2029 Annual Meeting of Stockholders at the 2026-06-10 meeting.

“Proposal No. 1: Election of Trustees: Alan B. Miller Robert F. McCadden Votes cast in favor 9,187,560 8,540,716 Votes cast against 222,081 868,560 Votes abstained 19,835 20,200 Non-votes 2,233,065 2,233,065”

Cardiff Oncology, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-11 meeting.

“Proposal 4. The advisory vote on the compensation of the Company's named executive officers was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 17,120,176 1,772,185 437,049 22,285,438”

Cardiff Oncology, Inc. shareholders approved Amendment to 2021 Equity Incentive Plan to increase number of shares issuable to 15,150,000 shares at the 2026-06-11 meeting.

“Proposal 3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 10,740,460 8,063,520 525,431 22,285,437”

Cardiff Oncology, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year 2026 at the 2026-06-11 meeting.

“Proposal 2. The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 40,239,508 1,070,807 304,529 4”

Cardiff Oncology, Inc. shareholders approved Election of six nominees for director at the 2026-06-11 meeting.

“Proposal 1 . All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the six (6) directors was as follows: Directors For Against Abstain Broker Non Vote Dr. James O. Armitage 18,806,657 0 522,756 22,285,435 Dr. Rodney Markin 18,647,050 0 682,361 22,285,437 Mani Mohindru, Ph.D. 18,942,979 0 386,435 22,285,434 Gary W. Pace, Ph.D. 18,877,743 0 451,668 22,285,437 Renee P. Tannenbaum, Pharm.D. 18,790,068 0 539,345 22,285,435 Lâle White 18,710,040 0 619,373 22,285,435”

Chicago Atlantic Real Estate Finance, Inc. shareholders approved Ratification of BDO USA, P.C. as independent registered public accounting firm at the 2026-06-11 meeting.

“Shareholders ratified the appointment of BDO USA, P.C., as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 based on the following votes: For Against Abstain Broker Non-Votes 12,995,674 72,645 94,847 -”

Chicago Atlantic Real Estate Finance, Inc. shareholders approved Election of five directors at the 2026-06-11 meeting.

“Shareholders elected five members of the board of directors of the Company, each to serve until the 2027 annual meeting of shareholders and until their successors are duly elected and qualified.”

MAGNITE, INC. shareholders approved Advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers at the 2026-06-08 meeting.

“1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTES 100,148,461 55,954 4,309,358 1,722,262 21,398,031”

MAGNITE, INC. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-08 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 93,243,703 11,274,849 1,717,483 21,398,031”

MAGNITE, INC. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the current fiscal year at the 2026-06-08 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 125,139,432 311,677 2,182,957 ---”

MAGNITE, INC. shareholders approved Election of three Class III directors at the 2026-06-08 meeting.

“Paul Caine 99,225,532 5,272,915 1,737,588 21,398,031 Doug Knopper 97,010,810 7,488,029 1,737,196 21,398,031 David Pearson 99,624,729 4,871,835 1,739,471 21,398,031”

Cogent Biosciences, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-04-13 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes Proposal 3. Advisory Vote on Executive Compensation 129,183,846 13,977,449 32,606 11,240,612”

Cogent Biosciences, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm at the 2026-04-13 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes Proposal 2. Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm 154,001,553 399,367 33,593 0”

Cogent Biosciences, Inc. shareholders approved Election of Directors at the 2026-04-13 meeting.

“At the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on were approved. The final voting results are set forth below. Votes For Votes Withheld Broker Non-Votes Proposal 1. Election of Directors • Chris Cain, Ph.D. 124,356,809 18,837,092 11,240,612 • Arlene Morris 120,180,517 23,013,384 11,240,612 • Todd Shegog 124,143,441 19,050,460 11,240,612”

ANNALY CAPITAL MANAGEMENT INC shareholders rejected Advisory approval of a stockholder proposal to adopt the right to act by written consent at the 2026-06-10 meeting.

“Proposal 4. Advisory approval of a stockholder proposal to adopt the right to act by written consent. For Against Abstentions Broker Non-Votes 125,082,555 291,896,484 4,621,461 155,868,572”

ANNALY CAPITAL MANAGEMENT INC shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025 at the 2026-06-10 meeting.

“Proposal 3. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. For Against Abstentions 560,444,015 14,398,788 2,626,269”

ANNALY CAPITAL MANAGEMENT INC shareholders approved Advisory approval of the Company’s executive compensation at the 2026-06-10 meeting.

“Proposal 2. Advisory approval of the Company’s executive compensation. For Against Abstentions Broker Non-Votes 389,682,344 28,637,561 3,280,595 155,868,572”

ANNALY CAPITAL MANAGEMENT INC shareholders approved Election of nine directors to serve until 2027 Annual Meeting at the 2026-06-10 meeting.

“Proposal 1. The election of nine directors to serve on the Board until the 2027 Annual Meeting and their successors are duly elected and qualify. Director For Against Abstentions Broker Non-Votes David L. Finkelstein 417,436,503 2,578,327 1,585,670 155,868,572 Thomas Hamilton 415,335,120 4,665,607 1,599,773 155,868,572 Kathy Hopinkah Hannan 414,192,894 5,788,267 1,619,339 155,868,572 Martin Laguerre 414,855,733 4,992,776 1,751,991 155,868,572 Manon Laroche 416,733,286 3,224,930 1,642,284 155,868,572 Eric A. Reeves 410,568,283 9,337,893 1,694,324 155,868,572 Glenn A. Votek 416,490,345 3,440,489 1,669,666 155,868,572 Scott Wede 414,954,811 4,999,439 1,646,250 155,868,572 Vicki Williams 412,748,880 7,163,754 1,687,866 155,868,572”

Sensata Technologies Holding plc shareholders approved Authorization to issue equity securities without preemption rights under section 570 of the U.K. Companies Act at the 2026-06-09 meeting.

“Companies Act: Votes For Votes Against Abstentions Broker Non-Votes 136,609,369 3,066,456 39,984 — This resolution was approved. 13. Ordinary resolution to authorize the Board of Directors, in accordance with section 551 of the U.K.”

Sensata Technologies Holding plc shareholders approved Authorization to issue equity securities under section 551 of the U.K. Companies Act at the 2026-06-09 meeting.

“Companies Act"), to exercise all powers of the Company to issue equity securities: Votes For Votes Against Abstentions Broker Non-Votes 139,464,127 215,131 36,551 — This resolution was approved. 12. Special resolution to authorize the Board of Directors, in accordance with section 570 of the U.K.”

Sensata Technologies Holding plc shareholders approved Approval of the form of share repurchase contracts and repurchase counterparties at the 2026-06-09 meeting.

“Special resolution to approve the form of share repurchase contracts and repurchase counterparties: Votes For Votes Against Abstentions Broker Non-Votes 137,266,934 2,410,513 38,362 — This resolution was approved. 11. Ordinary resolution to authorize the Board of Directors, in accordance with section 551 of the U.K.”

Sensata Technologies Holding plc shareholders approved Receipt of the Company's 2025 Annual Report and Accounts at the 2026-06-09 meeting.

“Ordinary resolution to receive the Company's 2025 Annual Report and Accounts: Votes For Votes Against Abstentions Broker Non-Votes 139,030,981 65,676 619,152 — This resolution was approved. 10. Special resolution to approve the form of share repurchase contracts and repurchase counterparties: Votes For Votes Against Abstentions Broker Non-Votes 137,266,934 2,410,513 38,362 — This resolution was approved.”

Sensata Technologies Holding plc shareholders approved Authorization for the Audit Committee to determine the Company's U.K. statutory auditor's reimbursement at the 2026-06-09 meeting.

“statutory auditor's reimbursement: Votes For Votes Against Abstentions Broker Non-Votes 139,635,785 11,550 68,474 — This resolution was approved. 9. Ordinary resolution to receive the Company's 2025 Annual Report and Accounts: Votes For Votes Against Abstentions Broker Non-Votes 139,030,981 65,676 619,152 — This resolution was approved.”

Sensata Technologies Holding plc shareholders approved Appointment of Deloitte Ireland LLP as the Company's U.K. statutory auditor for fiscal year 2026 at the 2026-06-09 meeting.

“statutory auditor for fiscal year 2026: Votes For Votes Against Abstentions Broker Non-Votes 139,647,984 14,084 53,741 — This resolution was approved. 8. Ordinary resolution to authorize the Audit Committee, for and on behalf of the Board, to determine the Company's U.K.”

Sensata Technologies Holding plc shareholders approved Approval of the Amendment to the 2021 Equity Incentive Plan at the 2026-06-09 meeting.

“Absmeier 134,114,510 971,144 31,778 4,598,377 Daniel L. Black 133,521,952 1,563,542 31,938 4,598,377 Lorraine A. Bolsinger 131,398,259 3,688,295 30,878 4,598,377 Philip Eyler 134,055,499 1,030,625 31,308 4,598,377 Laurie Schupmann 134,113,847 958,010 45,575 4,598,377 Constance E.”

Sensata Technologies Holding plc shareholders approved Advisory resolution to approve the Director Compensation Report at the 2026-06-09 meeting.

“Absmeier 134,114,510 971,144 31,778 4,598,377 Daniel L. Black 133,521,952 1,563,542 31,938 4,598,377 Lorraine A. Bolsinger 131,398,259 3,688,295 30,878 4,598,377 Philip Eyler 134,055,499 1,030,625 31,308 4,598,377 Laurie Schupmann 134,113,847 958,010 45,575 4,598,377 Constance E.”

Sensata Technologies Holding plc shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2026 at the 2026-06-09 meeting.

“Ordinary resolution to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2026: Votes For Votes Against Abstentions Broker Non-Votes 139,650,883 13,293 51,633 — This resolution was approved. 5. Ordinary advisory resolution to approve the Director Compensation Report: Votes For Votes Against Abstentions Broker Non-Votes 129,588,739 5,406,931 121,762 4,598,377 This resolution was approved.”